Download now: The Downfall of Cable, and the Rise of 5G!

Omicron Variant Is a Cause of Concern But Not Panic

Written by Monica Savaglia
Posted November 30, 2021

Just when we were starting to feel a little more optimistic about COVID there’s another variant that could pose a threat to the U.S. and the world. Market volatility is the last thing that we want to end on this year. We're all aware of how this pandemic has been extremely disruptive. No one wants to go back to lockdowns or other extreme restrictions again. We are burnt out.

This is why I’m not surprised that the market is experiencing the after-effects of the recent news of the Omicron variant. No one knows what to expect and most are expecting the worst. I’d be lying if I said it’s hard not to feel that way since we have endured so much in the past two years.

However, I don’t believe we’re at the same spot as we were back in February and March of 2020. Not to put it lightly since we’ve all been through a lot (and more than others), but we’ve managed to adjust our lives around the coronavirus and its variants in order to do what we need to do to survive. Our resilience is obvious. 

So while I do believe that we should be a little cautious of what’s going on and take note, I don’t think it would be in anyone’s best interests to act irrationally. We all want to come out at the end of this pandemic. I know it can be hard to remain optimistic but I know we'll get there. Especially when we have science on our side to help.

Are We Far From 2020?

That’s the difference between 2020 and now — we have treatments and vaccines that are helping us fight this pandemic with all that we've got. Getting to the end of this COVID pandemic is what we all want.

Biotech companies have been working hard these past two years to achieve just that. And now, they are continuing those efforts to help protect people from this recent variant. 

Jesse Bloom, an evolutionary biologist at the Fred Hutchinson Cancer Research Center in Seattle told the New York Times:

We really need to be vigilant about this new variant and preparing for it. Probably in a few weeks, we’ll have a better sense of how much this variant is spreading and how necessary it might be to push forward with a variant vaccine.

At the moment, many experts are unsure of what kind of damage this variant might be able to do and if current vaccines would be effective. That’s why vaccine makers Moderna, Pfizer-BioNTech, and Johnson & Johnson are preparing to reformulate their shots if necessary so that that reformulation would be available to the public when and if necessary. 

In a news release on Friday, Moderna said:

The recently described Omicron variant included mutations seen in the Delta variant that are believed to increase transmissibility and mutations seen in the Beta and Delta variants that are believed to promote immune escape. The combination of mutations represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity. 

We know mRNA vaccines like the ones from Moderna and Pfizer-BioNTech can adapt. A Pfizer spokeswoman, Jerica Pitts, said scientists “can adopt the current vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant.”

Scientists and health experts are doing what they have been doing throughout this entire pandemic — urging the public to wear masks, avoid crowded spaces, get vaccinated, get boosters if they are available to you.

Don't Panic — We Got Science Behind Us

On Monday, President Biden spoke to the country about the Omicron variant saying, “This variant is a cause for concern — not a cause for panic.”

The Omicron variant is just another realization of how COVID-19 is here to stay — at least for now. 

As tiring as it may sound, we will need to continue to take action against this virus with various treatments, whether that be with vaccines or other treatments that can kill symptoms and severe illness and death. 

I know people want to get back to life pre-pandemic, but building up immunity to this virus and ensuring that the spread of the virus is contained is crucial to getting back to a time where we don’t have to worry about variants disrupting our everyday lives.

And speaking of preventing the spread, there's a small biotech company that is producing a nasal spray with the ability to stop COVID-19 symptoms in seven days.

This nasal spray is part of these other remarkable scientific discoveries that are helping the world get past COVID-19. 

The interesting thing about this nasal spray company is that it’s relatively unknown, kind of similar to Moderna before it came out with its COVID-19 vaccine. Now Moderna is up over 2,000% since March 2020. 

This COVID-killing nasal spray company is expected to rise within the next year as it could get fast-track approval, which could easily put the company on track to similar gains to what Moderna has experienced over the past year with its COVID-fighting vaccine.

The small company could be on track to developing and producing one of the biggest medical breakthroughs — especially at a time when we need it the most. One of the best things to come out of this pandemic is having the opportunity to invest in companies like this COVID-killing nasal spray company. 

I wish I could talk to you more about it today, but I just don't have the time. There’s so much more that you need to know and I’m barely scratching the surface with this article. So if you've got time to spare today and want to learn more, check out this report. You'll learn more about this COVID-killing nasal spray and what lies ahead for the company that’s developing this groundbreaking product.

Until next time,

Monica Savaglia Signature Park Avenue Digest

Monica Savaglia

Monica Savaglia is Wealth Daily’s IPO specialist. With passion and knowledge, she wants to open up the world of IPOs and their long-term potential to everyday investors. She does this through her newsletter IPO Authority, a one-stop resource for everything IPO. She also contributes regularly to the Wealth Daily e-letter. To learn more about Monica, click here.

Buffett's Envy: 50% Annual Returns, Guaranteed